Eventide Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Eventide Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-600,000	Closed	-$26.1M	–	172
2023 Q3	$26.1M	Hold	600,000	–	–	0.47%	64
2023 Q2	$21.7M	Buy	600,000 +228,898	+62%	+$9.43M	0.37%	81
2023 Q1	$13.8M	Buy	371,102 +167,502	+82%	+$7.53M	0.25%	107
2022 Q4	$9.23M	Hold	203,600	–	–	0.18%	111
2022 Q3	$14.2M	Buy	203,600 +90,600	+80%	+$6.7M	0.28%	89
2022 Q2	$7.59M	Sell	113,000 -340,781	-75%	-$21.7M	0.16%	107
2022 Q1	$37.3M	Buy	453,781 +162,155	+56%	+$16.6M	0.58%	56
2021 Q4	$42.8M	Buy	291,626 +162,155	+125%	+$25.2M	0.55%	62
2021 Q3	$22.9M	Hold	129,471	–	–	0.3%	86
2021 Q2	$20.9M	Hold	129,471	–	–	0.28%	92
2021 Q1	$22.2M	Hold	129,471	–	–	0.33%	90
2020 Q4	$28.4M	Sell	129,471 -171,529	-57%	-$37.1M	0.44%	72
2020 Q3	$50M	Hold	301,000	–	–	0.98%	34
2020 Q2	$34.4M	Hold	301,000	–	–	0.75%	48
2020 Q1	$23.1M	Hold	301,000	–	–	0.75%	52
2019 Q4	$38.8M	Hold	301,000	–	–	1.09%	37
2019 Q3	$23.5M	Buy	301,000 +58,000	+24%	+$5.44M	0.77%	49
2019 Q2	$25M	Buy	+243,000	New	+$18.9M	0.76%	48

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Eventide Asset Management's MRTX Position: Q4 2023 in Review

Eventide Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 600,000 shares — an estimated $26.1M sold.

Eventide Asset Management first reported a position in MRTX in Q2 2019 and held it in 18 quarters. The position peaked at $50M in Q3 2020. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Eventide Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Eventide Asset Management sold 600,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $26.1M.
Eventide Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2019 and held it in 18 quarters.
Eventide Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $50M in Q3 2020.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Eventide Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.